A recent trial setback has dashed hopes for the imminent implementation of a groundbreaking cancer blood test within the NHS. The NHS aimed to validate the effectiveness of the initial multi-cancer blood test, often referred to as the “Holy Grail” by medical experts, in detecting cancer at earlier stages.
The test, known as the Galleri test, scrutinizes minuscule fragments of tumor DNA in the blood to identify the presence of cancer before symptoms manifest. Over 142,000 NHS patients aged 50 to 77 participated in a three-year assessment, with half receiving annual blood tests and the remainder undergoing standard NHS screenings.
Despite a £150 million investment, the trial did not achieve its primary objective of reducing the number of cancers diagnosed at stages three and four. Nevertheless, there were some encouraging outcomes, such as a notable decrease in stage four cancer diagnoses. Sir Harpal Kumar, the chief scientific officer at GRAIL, the test’s developer, highlighted that the rise in stage three cancer diagnoses might be attributed to early detection of some stage four cancers.
The Galleri test, created by the US-based biotechnology company GRAIL, is a Multi-Cancer Early Detection (MCED) blood test capable of screening for over 50 different cancer types from a single blood sample, often before symptoms manifest. The results of the trial, including both positive and negative findings, were presented at the American Society of Clinical Oncology’s annual conference.
Although GRAIL’s chief medical officer, Julie Gralow, indicated that the test may not receive NHS approval based on the trial data, Professor Richard Houlston from The Institute of Cancer Research cautioned against shifting focus from the primary goal. He emphasized that a comprehensive evaluation, considering patients’ survival rates over an extended period, is essential for assessing the test’s efficacy. However, the time-consuming nature of such trials poses challenges as technological advancements may render the test obsolete by completion.
Professor Peter Johnson, the national clinical director for cancer at NHS England, stressed the importance of detecting cancers at earlier stages to improve outcomes and save lives, aligning with the National Cancer Plan’s objectives. The NHS awaits detailed trial data to inform future decisions regarding the potential integration of the Galleri test into healthcare practices.
